Board of Directors
Thomas Monath, M.D. - Partner, Kleiner Perkins Caufield & Byers
Dr. Monath is a Partner, Pandemic and Biodefense Fund, Kleiner Perkins Caufield & Byers. He is also Adjunct Professor, Harvard School of Public Health. Between 1992 and 2006, Dr Monath was Chief Scientific Officer and an Executive Director, Acambis (a publicly traded biopharmaceutical company) where he directed R&D on dengue, West Nile, Japanese encephalitis, yellow fever, Clostridium difficile, and smallpox vaccines for defense against bioterrorism. Monath received his undergraduate degree from Harvard College and M.D. from Harvard Medical School and trained in internal medicine at the Peter Bent Brigham Hospital, Boston. COL Monath retired from the US Army in 1992 after 24 years in the uniformed services. Between 1973-1988, he was Director, Division of Vector-Borne Viral Diseases, Centers for Disease Control, Fort Collins CO and from 1989-92 Chief, Virology Division, US Army Medical Research Institute of Infectious Diseases (USAMRIID). He is on the editorial board of 5 scientific journals. He received the Nathanial A. Young Award (1984), the Richard M. Taylor Award (1996), and the Walter Reed Medal (2002) from the American Society of Tropical Medicine & Hygiene and was President of that Society (2004-05). He has served on numerous government and international committees on infectious diseases, biosecurity, World Health Organization expert committees and the National Vaccines Advisory Committee (USA). Dr. Monath has published over 340 papers and edited 6 books on the epidemiology, immunology and pathogenesis of viruses and on vaccine development.
Boris Lipkin - Venture Partner, VantagePoint Venture Partners
Boris is a partner in the VantagePoint Venture Partners Healthcare Practice Group, where he brings over 30 years of operating and high technology experience. Previously he served as the President and CEO of Therma-Wave, Inc., a NASDAQ listed semiconductor equipment company. He also served as Executive Vice President of ASML/Silicon Valley Group, Inc. and as Vice President and General Manager of Varian Associates after spending over 15 years in various management and engineering positions at IBM. In 2005 he was awarded the Ellis Island Medal of Honor. Boris has a MS in Electro Mechanical Engineering and an MBA from Stanford University.
Douglas Treco, Ph.D. - Independent Biotechnology Consultant and Visiting Scientist - Massachusetts General Hospital
Doug Treco co-founded Transkaryotic Therapies, Inc. (TKT, Cambridge, Massachusetts; acquired in 2005 by Shire plc), a multi-platform biopharmaceutical company developing protein and gene therapy products. His most recent position at TKT was Senior Vice President of Research and Development, with responsibility for all activities relating to research, development, and manufacture of biologicals. Doug is currently an independent consultant for the biotechnology and pharmaceutical industries and an Entrepreneur-in-Residence with Morgenthaler Ventures (Boston, MA). He is also a Visiting Scientist in the Center for Computational and Integrative Biology at Massachusetts General Hospital. He has authored numerous peer-reviewed publications and holds 35 US and European patents in the areas of protein production, gene mapping, and gene therapy. Doug received a Ph.D. degree in Biochemistry and Molecular Biology from the State University of New York at Stony Brook. He performed post-doctoral studies at the Salk Institute for Biological Studies and in the Department of Molecular Biology at Massachusetts General Hospital.
David J. Williams - chairman and CEO (retired), sanofi pasteur
David J. Williams, is the retired Chairman & CEO of sanofi pasteur, the vaccines business of sanofi-aventis Group. His 30-year tenure with the company was marked by his rise from Finance Manager to President and CEO. His leadership moved the company from a niche vaccine business to the global leader in vaccine development, production and sales. In addition, he was Chairman of the company's board of directors and a Co-Chair of the Supervisory Board of Sanofi Pasteur MSD, a 50-50 joint venture with Merck & Co. that markets and distributes vaccines in Europe. Prior to sanofi, Mr. Williams spent more than five years at Pricewaterhouse Coopers in their Audit and Healthcare Consulting Group. Mr. Williams serves on the Board of Directors of the Biotechnology Industry Organization (BIO), AllOne Health Group, VaxInnate , Blue Cross of Northeastern Pennsylvania and the Hospital Service Association of Northeastern Pennsylvania. For many years, he has been affiliated with the University of Scranton, from which he has his undergraduate degree, is a past member of the Board of Trustees and Board of Regents. He is also one of the founding Board Members of the Medical Education Development Consortium, which is creating the first medical college in Northeastern Pennsylvania. Mr. Williams is currently a consultant to several vaccine and biotech companies.
Scot Galliher - SG Capital
Scot is a founding investor in Xcellerex. He has spent 25 years working with high growth companies in the financial services industry. Most recently he advised J. Joe Ricketts, Chairman of Ameritrade, on the $3.5 billion merger of Ameritrade and TD Waterhouse and the purchase of a minority stake in Ameritrade by TD Bank. Previously Mr. Galliher was a senior executive at Shinsei Bank in Japan in charge of Electronic Commerce and a partner at Conning Capital Partners, a mid-sized venture capital firm investing $550 million in high growth financial services companies. Prior to that Scot co-founded the Financial Institutions Technology Group at Goldman Sachs where he specialized in online banks, brokerages and electronic exchanges and worked on approximately $3 billion in mergers, IPO's, and debt transactions.
Joseph Zakrzewski - President and Chief Executive Officer
Mr. Zakrzewski is currently the President, Chief Executive Officer and a Director of Xcellerex, a privately held company focusing on commercializing its proprietary next generation manufacturing technology for biotherapeutics and vaccines. Mr. Zakrzewski recently served as the Chief Operating Officer of Reliant Pharmaceuticals, a specialty pharmaceutical company focused on cardiovascular drugs from 2005 through the first quarter of 2007. Mr. Zakrzewski had responsibility for the company's pharmaceutical operations including, R&D, business development, supply chain/manufacturing, quality, IT, and compliance. From 1988 to 2004, Mr. Zakrzewski served in a variety of executive level capacities at Eli Lilly & Company including R&D, manufacturing, finance and business development. His most recent position was Vice President, Corporate Business Development, where he had global responsibility for all business development activities on a global basis. Mr. Zakrzewski received a BS in Chemical Engineering in 1986; an MS in Biochemical Engineering from Drexel University in 1988, and received an MBA in Finance in 1992 from Indiana University. In addition to his role on the Xcellerex Board of Directors, Mr. Zakrzewski also serves as a member of the Board of Insulet Corporation and is Chairman of the Boards of Promedior Inc. and Zelos Therapeutics.
are developed, manufactured & commercialized.
